why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
First received: April 10, 2025

Clinical Trial: Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Pulmonary Arterial Hypertension (PAH)

Study Type: INTERVENTIONAL


Official Title: Randomized, Single Oral Dose, Two-period, Two-treatment, Two-sequence Open-label, Crossover, Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 40

Brief Summary: Randomized, single oral dose, two-period, two-treatment, two-sequence open-label, crossover, bioequivalence study to compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag), in healthy subjects under fed conditions.

Read more